{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:10:12Z","timestamp":1790716212191,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI130470"],"award-info":[{"award-number":["R01AI130470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-148948"],"award-info":[{"award-number":["PJT-148948"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000875","name":"Pew Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jim.2018.03.009","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T12:32:28Z","timestamp":1522499548000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins"],"prefix":"10.1016","volume":"457","author":[{"given":"Chung-An M.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Baglaenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario M.","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-5204","authenticated-orcid":false,"given":"Patrick","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3178","authenticated-orcid":false,"given":"Juan Carlos","family":"Zuniga-Pflucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina W.","family":"Rosbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan E.","family":"Wither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood-2008-02-142745","article-title":"STAT3 is required for IL-21-induced secretion of IgE from human naive B cells","volume":"112","author":"Avery","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jim.2018.03.009_bb0010","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jim.2018.03.009_bb0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.3659","article-title":"Applications of CRISPR technologies in research and beyond","volume":"34","author":"Barrangou","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2018.03.009_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10934","article-title":"Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system","volume":"7","author":"Cheong","year":"2016","journal-title":"Nat. Commun."},{"issue":"44","key":"10.1016\/j.jim.2018.03.009_bb0025","doi-asserted-by":"crossref","first-page":"12514","DOI":"10.1073\/pnas.1613884113","article-title":"Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL\/6 Cas9 transgenic mouse line","volume":"113","author":"Chu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jim.2018.03.009_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4939-7095-7_12","article-title":"CRISPR\/Cas9-mediated in vitro mutagenesis in GC-like B cells","volume":"1623","author":"Chu","year":"2017","journal-title":"Methods Mol. Biol."},{"issue":"6121","key":"10.1016\/j.jim.2018.03.009_bb0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jim.2018.03.009_bb0040","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1084\/jem.20130323","article-title":"Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells","volume":"210","author":"Deenick","year":"2013","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jim.2018.03.009_bb0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.jim.2018.03.009_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/096120339200100203","article-title":"Autoimmunity, polyclonal B-cell activation and infection","volume":"1","author":"Granholm","year":"1992","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jim.2018.03.009_bb0055","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.0.CO;2-9","article-title":"Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4","volume":"28","author":"Hasbold","year":"1998","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0060","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.celrep.2016.09.080","article-title":"A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells","volume":"17","author":"Hultquist","year":"2016","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.jim.2018.03.009_bb0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","article-title":"Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells","volume":"26","author":"Hung","year":"2017","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.jim.2018.03.009_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku749","article-title":"Multiplex CRISPR\/Cas9-based genome engineering from a single lentiviral vector","volume":"42","author":"Kabadi","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.jim.2018.03.009_bb0075","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nprot.2011.301","article-title":"AAV-mediated gene targeting methods for human cells","volume":"6","author":"Khan","year":"2011","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.jim.2018.03.009_bb0080","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.4049\/jimmunol.168.12.6314","article-title":"B cell receptor- and beta 2-adrenergic receptor-induced regulation of B7-2 (CD86) expression in B cells","volume":"168","author":"Kohm","year":"2002","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0085","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jim.2018.03.009_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2017.08.007","article-title":"Generation and CRISPR\/Cas9 editing of transformed progenitor B cells as a pseudo-physiological system to study DNA repair gene function in V(D)J recombination","volume":"451","author":"Lenden Hasse","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2018.03.009_bb0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"elife"},{"issue":"10","key":"10.1016\/j.jim.2018.03.009_bb0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.3721","article-title":"Genome editing: a tool for research and therapy: targeted genome editing hits the clinic","volume":"20","author":"Lombardo","year":"2014","journal-title":"Nat. Med."},{"issue":"6201","key":"10.1016\/j.jim.2018.03.009_bb0105","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jim.2018.03.009_bb0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0115","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/eji.1830230510","article-title":"Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines","volume":"23","author":"Maliszewski","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"26","key":"10.1016\/j.jim.2018.03.009_bb0120","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jim.2018.03.009_bb0125","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jim.2018.03.009_bb0130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.molcel.2016.06.037","article-title":"DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks","volume":"63","author":"van Overbeek","year":"2016","journal-title":"Mol. Cell"},{"issue":"7601","key":"10.1016\/j.jim.2018.03.009_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9","volume":"533","author":"Paquet","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jim.2018.03.009_bb0140","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nbt.3583","article-title":"Analyzing CRISPR genome-editing experiments with CRISPResso","volume":"34","author":"Pinello","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jim.2018.03.009_bb0145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jim.2018.03.009_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12463","article-title":"Non-homologous DNA increases gene disruption efficiency by altering DNA repair outcomes","volume":"7","author":"Richardson","year":"2016","journal-title":"Nat. Commun."},{"issue":"33","key":"10.1016\/j.jim.2018.03.009_bb0155","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.jim.2018.03.009_bb0160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"9\u201310","key":"10.1016\/j.jim.2018.03.009_bb0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00335-015-9565-z","article-title":"CRISPR-Cas9-mediated genome editing and guide RNA design","volume":"26","author":"Wiles","year":"2015","journal-title":"Mamm. Genome"},{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0170","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.immuni.2012.02.009","article-title":"Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition","volume":"36","author":"Yang","year":"2012","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jim.2018.03.009_bb0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.stem.2017.06.016","article-title":"Engineered epidermal progenitor cells can correct diet-induced obesity and diabetes","volume":"21","author":"Yue","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.jim.2018.03.009_bb0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175918300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175918300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:33:05Z","timestamp":1758299585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175918300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":36,"alternative-id":["S0022175918300073"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2018.03.009","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2018.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}